Staley Capital Advisers Inc. Purchases 54,140 Shares of Pfizer Inc. $PFE

Staley Capital Advisers Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 2.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,035,654 shares of the biopharmaceutical company’s stock after purchasing an additional 54,140 shares during the period. Pfizer comprises 2.4% of Staley Capital Advisers Inc.’s holdings, making the stock its 16th biggest position. Staley Capital Advisers Inc.’s holdings in Pfizer were worth $57,161,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Frank Rimerman Advisors LLC boosted its position in Pfizer by 6.6% during the 1st quarter. Frank Rimerman Advisors LLC now owns 174,884 shares of the biopharmaceutical company’s stock valued at $4,911,000 after acquiring an additional 10,872 shares in the last quarter. PCB Capital LLC lifted its stake in shares of Pfizer by 4.0% during the 1st quarter. PCB Capital LLC now owns 39,758 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 1,544 shares during the last quarter. Lmcg Investments LLC lifted its stake in shares of Pfizer by 15.5% during the 1st quarter. Lmcg Investments LLC now owns 43,217 shares of the biopharmaceutical company’s stock worth $1,214,000 after purchasing an additional 5,800 shares during the last quarter. Flatrock Wealth Partners LLC bought a new stake in Pfizer during the first quarter valued at about $241,000. Finally, Jackson Thornton Wealth Management LLC grew its stake in Pfizer by 15.4% in the first quarter. Jackson Thornton Wealth Management LLC now owns 14,668 shares of the biopharmaceutical company’s stock valued at $395,000 after purchasing an additional 1,953 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE PFE opened at $24.05 on Thursday. The company has a market cap of $137.05 billion, a price-to-earnings ratio of 18.36 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock’s fifty day moving average price is $25.46 and its 200 day moving average price is $26.20. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer’s dividend payout ratio is currently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer continues to draw attention from income investors because of its large dividend payout, and some market commentary frames the stock as a potential value play for buyers seeking yield. How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum
• Positive Sentiment: Analyst and media coverage continues to highlight Pfizer as an attractively priced healthcare stock after the recent FDA approval for IBRANCE, which could support the investment case if pipeline progress continues. Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?
• Neutral Sentiment: Pfizer is also attracting broad investor attention in screening and “most searched” lists, which reflects heightened trading interest but does not by itself change the fundamentals. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: JPMorgan lowered its price target on Pfizer and kept a neutral stance, signaling limited near-term upside in the bank’s view and likely contributing to the stock’s weakness. Pfizer price target cut news
• Negative Sentiment: Several articles questioned whether Pfizer’s dividend is riskier than it appears, which can dampen enthusiasm even though the stock is known for income appeal. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think
• Negative Sentiment: News coverage about structural problems at Pfizer’s former headquarters added another negative headline, even though one report said the issues were related to construction rather than steel quality. ‘Failures happen during construction’: Office-to-residential conversions are all over NYC, but failures usually get fixed before they get worse

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $28.00 in a research note on Monday. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. Guggenheim boosted their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. UBS Group restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.56.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.